信迪利单抗联合诱导-同步放化疗治疗局部晚期鼻咽癌的经济学评价  

Economic Evaluation of Sintilimab Combined with Induction-concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma

作　　者：龚楚红 孙宇阳 陶田甜 李歆[2] GONG Chuhong;SUN Yuyang;TAO Tiantian;LI Xin(Department of Education and Teaching,Jiangsu Province Hospital of Traditional Chinese Medicine,Nan-jing 210029,China;School of Pharmacy,Nanjing Medical University,Nanjing 211166,China)

机构地区：[1]江苏省中医院教育教学处,南京210029 [2]南京医科大学药学院,南京211166

出　　处：《药学与临床研究》2025年第1期78-83,共6页Pharmaceutical and Clinical Research

基　　金：国家自然科学基金资助项目(72074123);江苏省药学会科研基金项目(JSPA-KY-202401,JSPA-KY-202403)。

摘　　要：目的:评估信迪利单抗联合诱导-同步放化疗对比标准诱导-同步放化疗在局部晚期鼻咽癌治疗中的经济性。方法:基于Ⅲ期CONTINUUM临床试验数据构建马尔可夫模型。模型将患者分为无事件生存期(EFS)、疾病进展(PD)和死亡(D)三个健康状态,设定21天为循环周期,研究时限为终身,贴现率为5%。支付意愿阈值(WTP)设定为获得一个单位的健康产出(质量调整生命年,QALY)所支付的金额(2023年中国人均国内生产总值),即89358元/QALY。结果:信迪利单抗组较标准治疗组的增量效用为3.192 QALYs,增量成本为242736.41元,增量成本效果比(ICER)为76044.92元/QALY,低于WTP。结论:与标准治疗组相比,信迪利单抗组具有经济性。Objective:To evaluate the cost-effectiveness of sintilimab combined with induction-concurrent chemoradiotherapy compared with standard induction-concurrent chemoradiotherapy for the treat-ment of locoregionally advanced nasopharyngeal carcinoma(LA-NPC).Methods:A Markov model was developed based on the phaseⅢCONTINUUM clinical trial data from the perspective of the Chinese healthcare system.Patients were categorized into three health states:event-free survival(EFS),progressed disease(PD)and death(D).The model adopted a 21-day cycle length with a lifetime time horizon and a discount rate of 5%.The willingness-to-pay(WTP)threshold was set at the per capita gross domestic prod-uct(GDP)of China in 2023 for 1 quality-adjusted life year(QALY),namely 89358 CNY/QALY.Results:Compared with the standard treatment group,the sintilimab group demonstrated an incremental utility of 3.192 QALYs and an incremental cost of 242736.41 CNY,resulting in an incremental cost-effectiveness ratio(ICER)of 76044.92 CNY/QALY,which was below the WTP threshold.Conclusion:Sintilimab com-bined with induction-concurrent chemoradiotherapy is cost-effective compared with the standard treatment for LA-NPC.

关 键 词：信迪利单抗 局部晚期鼻咽癌 诱导-同步放化疗 成本效用分析 

分 类 号：R956[医药卫生—药学]